SUMMIT THERAPEUTICS INC., 10-Q filed on 11/4/2026
Quarterly Report
v3.26.3
Cover - shares
9 Months Ended
Sep. 30, 2026
Oct. 30, 2026
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2026  
Document Transition Report false  
Entity File Number 001-36866  
Entity Registrant Name Summit Therapeutics Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 37-1979717  
Entity Address, Address Line One 601 Brickell Key Drive, Suite 1000  
Entity Address, City or Town Miami  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33131  
City Area Code 305  
Local Phone Number 203-2034  
Title of 12(b) Security Common Stock, $0.01 par value per share  
Trading Symbol SMMT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   799,763,918
Entity Central Index Key 0001599298  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q3  
Amendment Flag false  
v3.26.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 150,811 $ 225,266
Restricted cash 316 316
Short-term investments 478,976 488,182
Prepaid expenses and other current assets 30,625 6,537
Total current assets 660,728 720,301
Non-current assets:    
Property and equipment, net 2,531 1,059
Operating lease right-of-use assets 18,658 20,616
Goodwill 1,975 2,001
Other assets 8,958 7,205
Total assets 692,850 751,182
Current liabilities:    
Accounts payable 32,715 20,292
Accrued liabilities 55,934 32,100
Accrued compensation 15,900 14,925
Operating lease liabilities, current portion 3,849 3,388
Other current liabilities 1,828 2,283
Total current liabilities 110,226 72,988
Non-current liabilities:    
Operating lease liabilities, net of current portion 16,133 17,502
Other non-current liabilities 1,808 1,832
Total liabilities 128,167 92,322
Commitments and contingencies (Note 13)
Stockholders' equity:    
Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at September 30, 2026 and December 31, 2025, respectively 0 0
Common stock, $0.01 par value: 1,000,000,000 shares authorized; 799,726,418 and 775,371,200 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively 7,997 7,754
Additional paid-in capital 3,467,052 2,947,805
Accumulated other comprehensive loss (2,698) (2,540)
Accumulated deficit (2,907,668) (2,294,159)
Total stockholders' equity 564,683 658,860
Total liabilities and stockholders' equity $ 692,850 $ 751,182
v3.26.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 1,000,000,000 1,000,000,000
Common stock, shares issued (in shares) 799,726,418 775,371,200
Common stock, shares, outstanding (in shares) 799,726,418 775,371,200
v3.26.3
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Operating expenses:        
Research and development [1] $ 169,131 $ 131,096 $ 459,482 $ 390,382
General and administrative 45,480 103,115 170,837 479,117
Total operating expenses 214,611 234,211 630,319 869,499
Other income, net 6,226 2,418 16,810 9,085
Net loss $ (208,385) $ (231,793) $ (613,509) $ (860,414)
Net loss per share:        
Basic (in dollars per share) $ (0.26) $ (0.31) $ (0.78) $ (1.16)
Diluted (in dollars per share) $ (0.26) $ (0.31) $ (0.78) $ (1.16)
Weighted average common shares outstanding:        
Basic (in shares) 798,197,278 743,415,917 784,027,255 741,388,536
Diluted (in shares) 798,197,278 743,415,917 784,027,255 741,388,536
Other comprehensive income (loss):        
Foreign currency translation adjustments $ 8 $ 43 $ 126 $ (291)
Unrealized loss on short-term investments (41) 0 (284) (133)
Comprehensive loss $ (208,418) $ (231,750) $ (613,667) $ (860,838)
[1] Refer to Note 12 – Related Party Transactions for expenses incurred.
v3.26.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   737,626,004      
Beginning balance at Dec. 31, 2024 $ 388,748 $ 7,376 $ 1,598,230 $ (2,285) $ (1,214,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (in shares) [1]   3,983,386      
Issuance of common stock under stock purchase plans and exercise of stock options and warrants [1] 7,677 $ 40 7,637    
Stock-based compensation 11,096   11,096    
Net other comprehensive (loss) gain (278)     (278)  
Net loss (62,913)       (62,913)
Ending balance (in shares) at Mar. 31, 2025   741,609,390      
Ending balance at Mar. 31, 2025 344,330 $ 7,416 1,616,963 (2,563) (1,277,486)
Beginning balance (in shares) at Dec. 31, 2024   737,626,004      
Beginning balance at Dec. 31, 2024 388,748 $ 7,376 1,598,230 (2,285) (1,214,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (860,414)        
Ending balance (in shares) at Sep. 30, 2025   744,442,533      
Ending balance at Sep. 30, 2025 192,263 $ 7,444 2,262,515 (2,709) (2,074,987)
Beginning balance (in shares) at Mar. 31, 2025   741,609,390      
Beginning balance at Mar. 31, 2025 344,330 $ 7,416 1,616,963 (2,563) (1,277,486)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares) [1]   1,197,282      
Issuance of common stock upon exercise of stock options [1] 2,222 $ 12 2,210    
Stock-based compensation 478,784   478,784    
Net other comprehensive (loss) gain (189)     (189)  
Net loss (565,708)       (565,708)
Ending balance (in shares) at Jun. 30, 2025   742,806,672      
Ending balance at Jun. 30, 2025 259,439 $ 7,428 2,097,957 (2,752) (1,843,194)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (in shares)   313,068      
Issuance of common stock under stock purchase plans and exercise of stock options and warrants 2,049 $ 3 2,046    
Proceeds from at-the-market offering, net of commissions and offering costs (in shares)   1,322,793      
Proceeds from at-the-market offering, net of commissions and offering costs 31,764 $ 13 31,751    
Stock-based compensation 130,761   130,761    
Net other comprehensive (loss) gain 43     43  
Net loss (231,793)       (231,793)
Ending balance (in shares) at Sep. 30, 2025   744,442,533      
Ending balance at Sep. 30, 2025 $ 192,263 $ 7,444 2,262,515 (2,709) (2,074,987)
Beginning balance (in shares) at Dec. 31, 2025 775,371,200 775,371,200      
Beginning balance at Dec. 31, 2025 $ 658,860 $ 7,754 2,947,805 (2,540) (2,294,159)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (in shares)   646,274      
Issuance of common stock under stock purchase plans and exercise of stock options and warrants 3,797 $ 6 3,791    
Stock-based compensation 72,791   72,791    
Net other comprehensive (loss) gain (92)     (92)  
Net loss (189,424)       (189,424)
Ending balance (in shares) at Mar. 31, 2026   776,017,474      
Ending balance at Mar. 31, 2026 $ 545,932 $ 7,760 3,024,387 (2,632) (2,483,583)
Beginning balance (in shares) at Dec. 31, 2025 775,371,200 775,371,200      
Beginning balance at Dec. 31, 2025 $ 658,860 $ 7,754 2,947,805 (2,540) (2,294,159)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss $ (613,509)        
Ending balance (in shares) at Sep. 30, 2026 799,726,418 799,726,418      
Ending balance at Sep. 30, 2026 $ 564,683 $ 7,997 3,467,052 (2,698) (2,907,668)
Beginning balance (in shares) at Mar. 31, 2026   776,017,474      
Beginning balance at Mar. 31, 2026 545,932 $ 7,760 3,024,387 (2,632) (2,483,583)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon exercise of stock options (in shares)   670,453      
Issuance of common stock upon exercise of stock options 3,665 $ 7 3,658    
Proceeds from at-the-market offering, net of commissions and offering costs (in shares) [1]   16,432,435      
Proceeds from at-the-market offering, net of commissions and offering costs [1] 227,413 $ 164 227,249    
Stock-based compensation 68,706   68,706    
Net other comprehensive (loss) gain (33)     (33)  
Net loss (215,700)       (215,700)
Ending balance (in shares) at Jun. 30, 2026   793,120,362      
Ending balance at Jun. 30, 2026 629,983 $ 7,931 3,324,000 (2,665) (2,699,283)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock under stock purchase plans and exercise of stock options and warrants (in shares)   406,901      
Issuance of common stock under stock purchase plans and exercise of stock options and warrants 2,605 $ 4 2,601    
Proceeds from at-the-market offering, net of commissions and offering costs (in shares)   6,199,155      
Proceeds from at-the-market offering, net of commissions and offering costs 92,827 $ 62 92,765    
Stock-based compensation 47,686   47,686    
Net other comprehensive (loss) gain (33)     (33)  
Net loss $ (208,385)       (208,385)
Ending balance (in shares) at Sep. 30, 2026 799,726,418 799,726,418      
Ending balance at Sep. 30, 2026 $ 564,683 $ 7,997 $ 3,467,052 $ (2,698) $ (2,907,668)
[1] Refer to Note 12 – Related Party Transactions
v3.26.3
Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Sep. 30, 2025
Statement of Stockholders' Equity [Abstract]      
Adjustments to additional paid in capital, stock issued, issuance costs $ 1,283 $ 3,463 $ 794
v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows from operating activities:    
Net loss $ (613,509) $ (860,414)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of discount on short-term investments (11,122) (3,989)
Unrealized foreign exchange loss (gain) 230 (414)
Depreciation 175 104
Stock-based compensation 189,183 620,641
Change in operating assets and liabilities:    
Prepaid expenses and other current assets (24,087) 3,658
Other long-term assets (1,753) 0
Accounts payable 12,714 17,448
Accrued liabilities 23,394 7,397
Accrued compensation 975 (1,047)
Other current liabilities (455) 134
Other non-current liabilities (24) 82
Other long-term assets 0 (4,528)
Operating lease right-of-use assets and lease liabilities, net 1,050 (64)
Net cash used in operating activities (423,229) (220,992)
Cash flows from investing activities:    
Maturities and sales of short-term investments 672,311 311,340
Purchase of short-term investments (652,267) 0
Purchases of property and equipment (1,550) (493)
Net cash provided by investing activities 18,494 310,847
Cash flows from financing activities:    
Proceeds from the issuance of common stock under at-the-market offering, net of commissions [1] 320,241 31,764
Proceeds received related to employee stock purchase plan and exercise of stock options 10,066 4,633
Proceeds from exercise of warrants [1] 0 7,315
Net cash provided by financing activities 330,307 43,712
Effect of exchange rate changes on cash (27) 121
(Decrease) increase in cash, cash equivalents and restricted cash (74,455) 133,688
Cash, cash equivalents and restricted cash at beginning of period 225,582 105,187
Cash, cash equivalents and restricted cash at end of period 151,127 238,875
Reconciliation of cash, cash equivalents and restricted cash:    
Cash and cash equivalents 150,811 238,554
Restricted cash 316 321
Total cash, cash equivalents and restricted cash 151,127 238,875
Supplemental Disclosure of Non-Cash Investing and Financing Activities:    
Offering costs included in accounts payable and accrued expenses 0 85
Leased assets obtained in exchange for operating lease liabilities 709 815
Unpaid amounts related to property and equipment, net $ 439 $ 164
[1] Refer to Note 12 – Related Party Transactions
v3.26.3
Organization
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline product candidate is designed with the goal to become patient-friendly, new-era standard-of-care medicine, in the therapeutic area of oncology.

The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. On December 5, 2022, the Company entered into the License Agreement with Akeso, Inc. and its affiliates (collectively, “Akeso”) pursuant to which the Company has in-licensed intellectual property rights related to ivonescimab (as amended, the “License Agreement”), as further described in Note 4. Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan. The License Agreement and transaction closed in January 2023 following customary waiting periods. On June 3, 2024, the Company entered into an amendment to the License Agreement (the “Second Amendment”) with Akeso to expand its territories covered under the License Agreement to also include Latin America, including Mexico and all countries in Central America and South America, the Middle East and Africa (collectively, and as expanded, the “Licensed Territory”). The Company’s operations are focused on the development of ivonescimab and other future activities, as the Company determines.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. All intercompany accounts and transactions have been eliminated in consolidation. The interim financial data as of September 30, 2026 and for the three and nine months ended September 30, 2026 are unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The condensed consolidated balance sheet presented as of December 31, 2025 has been derived from the consolidated audited financial statements as of that date. The results of the period are not necessarily indicative of full year results or any other interim period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Company’s Annual Report. The financial results of the Company’s activities are reported in United States Dollars.

Use of Estimates

The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Liquidity and Capital Resources

During the three and nine months ended September 30, 2026, the Company incurred a net loss of $208,385 and $613,509, respectively, and cash used in operating activities for the nine months ended September 30, 2026 was $423,229. As of
September 30, 2026, the Company had an accumulated deficit of $2,907,668, cash and cash equivalents of $150,811 and short-term investments of $478,976. The Company expects to continue to generate operating losses for the foreseeable future.

Subsequent to the quarter ended September 30, 2026, the Company received gross proceeds of $2,000,000 from AstraZeneca Holdings B.V, a subsidiary of AstraZeneca plc (together with its subsidiaries, “AstraZeneca”) in connection with the closing of the AstraZeneca Equity Investment (as defined below). For additional detail on the AstraZeneca Equity Investment, refer to Note 10 AstraZeneca Equity Investment. With the AstraZeneca Equity Investment, the Company has evaluated and concluded that its cash, cash equivalents and short-term investments provide sufficient cash to fund its operating cash needs for at least the next 12 months from the date of issuance of these unaudited condensed consolidated financial statements.
Until the Company can generate substantial revenue and achieve profitability, the Company will need to raise additional capital to fund its ongoing operations and capital needs. The Company continues to evaluate options to further finance its operating cash needs for its product candidates through a combination of some, or all, of the following: equity and debt offerings, collaborations, strategic alliances, grants and clinical trial support from government entities, philanthropic, non-government and not-for-profit organizations, and marketing, distribution or licensing arrangements. There is no assurance, however, that additional financing will be available when needed or that management of the Company will be able to obtain financing on terms acceptable to the Company. If the Company is unable to obtain funding when required in the future, the Company could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.
v3.26.3
Summary of Significant Accounting Policies and Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies and Recent Accounting Pronouncements Summary of Significant Accounting Policies and Recent Accounting Pronouncements
Significant Accounting Policies

There have been no significant changes to the Company’s significant accounting policies used in the preparation of these unaudited condensed consolidated financial statements for the nine months ended September 30, 2026 as compared with those discussed in Note 2 to the consolidated financial statements in the Company’s Annual Report.

Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”) which requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures. The guidance is to be applied prospectively, with the option for retrospective application and is effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, “Narrow-Scope Improvements”, which is intended to improve the navigability of the guidance in ASC 270 and clarify when the guidance is applicable. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s consolidated financial statements and related disclosures.

Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the SEC did not or are not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.
v3.26.3
Segment Reporting
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s chief operating decision makers (the “CODM function”), which are the Company’s Co-Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, and Chief Operating Officer and Chief Financial Officer, Mr. Soni, utilize consolidated net loss that is reported on the unaudited condensed consolidated statement of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company. The CODM function
approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company’s consolidated operating budget. The CODM function views the Company’s operations and manages its business on a consolidated basis and as a single reportable operating segment. The CODM function is regularly provided with the following significant segment expenses:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Oncology clinical trial related costs$122,612 $75,236 $327,146 $179,423 
Compensation related costs, excluding stock-based compensation32,688 21,469 87,116 54,123 
Stock-based compensation47,686 130,761 189,183 620,641 
Other expenses (1)
11,625 6,745 26,874 15,312 
Total segment expenses214,611 234,211 630,319 869,499 
Other income, net6,226 2,418 16,810 9,085 
Net loss$(208,385)$(231,793)$(613,509)$(860,414)

(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.

As of September 30, 2026 and December 31, 2025, substantially all of the Company’s long-lived assets are located in the United States.
v3.26.3
Akeso License and Collaboration Agreement
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Akeso License and Collaboration Agreement Akeso License and Collaboration Agreement
On December 5, 2022, the Company entered into the License Agreement with Akeso pursuant to which the Company is in-licensing its bispecific antibody, ivonescimab. The License Agreement and transaction closed in January 2023 following customary waiting periods.

Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the Summit Licensed Territory, is a novel, potential first-in-class bispecific antibody intending to combine the effect of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF into a single molecule. Ivonescimab was invented to bring two well-established oncology targeted mechanisms together. Ivonescimab is currently in clinical development and, pursuant to the terms of the License Agreement, Summit will design and conduct the clinical trial activities to support regulatory filings in the Licensed Territory that Summit will submit.

Pursuant to the terms of the License Agreement, Summit will have final decision-making authority with respect to clinical development strategy and execution in the Licensed Territory. For co-joined studies in which both Summit and Akeso participate, mutual agreement is required for material decisions; Summit retains the exclusive decision making with respect to participating in, and continuing its participation in, co-joined studies in the Licensed Territory. Pursuant to the terms of the License Agreement, Summit will have final decision-making authority with respect to commercial strategy, pricing and reimbursement and other commercialization matters in the Licensed Territory. In connection with the License Agreement, the Company agreed to purchase a certain portion of drug substance and/or drug product for clinical and commercial supply and to enter into a supply agreement with Akeso. Summit is not assuming any liabilities (including contingent liabilities), acquiring any physical assets or trade names, or hiring or acquiring any employees from Akeso in connection with the License Agreement. Through the License Agreement, the Company obtained the rights to develop and commercialize ivonescimab in the United States, Canada, Europe, and Japan.
In exchange for the rights obtained, the Company made an upfront payment of $500,000 to Akeso, of which $274,900 was paid in cash and, pursuant to the License Agreement and Issuance Agreement, Akeso elected to receive 10,000,000 shares of the Company’s common stock, par value $0.01 per share (“common stock”) in lieu of $25,100 in cash. The remaining $200,000 amount of the upfront payment was paid on March 6, 2023.
Effective June 3, 2024, the Company and Akeso entered into the Second Amendment to the License Agreement to expand the Company’s territories covered under the License Agreement to include the Latin America, Middle East and Africa regions. Pursuant to the Second Amendment, the Company paid an upfront payment to Akeso of $15,000 in the third quarter of 2024. Akeso will also be eligible to receive up to an additional $55,000 upon the achievement of certain commercial milestones. Except as specifically modified by the Second Amendment, the terms and conditions of the License Agreement remain in full force and effect.

The Company has accounted for the License Agreement and Second Amendment to acquire the rights to develop and commercialize ivonescimab as the acquisition of an asset. All of the consideration relates to ivonescimab and technological feasibility of the asset has not yet been established since ivonescimab is in clinical development. As such, the Company has expensed the consideration as acquired in-process research and development upon closing of the transaction in the unaudited condensed consolidated statement of operations and comprehensive loss. There was no acquired in-process research and development expense for the three and nine months ended September 30, 2026 and 2025, respectively. In addition to the payments already made to Akeso, under the License Agreement and Second Amendment, there are additional potential milestone payments of up to $4,555,000, as Akeso will be eligible to receive regulatory milestones of up to $1,050,000 and commercial milestones of up to $3,505,000. In addition, Akeso will be eligible to receive low double-digit royalties on net sales.
v3.26.3
Other Income, Net
9 Months Ended
Sep. 30, 2026
Other Income and Expenses [Abstract]  
Other Income, Net Other Income, Net
The following table sets forth the components of other income, net:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Foreign currency loss $(273)$(362)$(425)$(484)
Investment income (1)
6,499 2,780 16,735 9,622 
Other (2)
— — 500 (53)
Total
$6,226 $2,418 $16,810 $9,085 

(1) Investment income relates to the Company’s money market funds, certificate of deposit and U.S. government treasury bills. Refer to Note 7 for details.

(2) In June 2026, the Company entered into an asset purchase agreement (the “APA”) with a third party. Pursuant to the APA, the Company sold the asset relating to the pharmaceutical compound known as ridinilazole. In consideration for such assignment of rights, the third party has made an upfront non-refundable payment to the Company of $500. Additionally, the third party has also agreed to make additional payments totaling $1,500 that are contingent upon the achievement of certain regulatory milestones, sales-based milestone payments of up to $103,000, as well as quarterly royalty payments that are based on a single digit percentage of net sales for certain products covered by the assigned and transferred patent rights. The Company did not have any amounts capitalized related to the underlying portfolio of patents, nor was any write-down of assets recorded upon executing the APA. The Company received the payment of $500 from the third party in June 2026 and recognized the $500 within other income, net on the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2026. The Company does not have any ongoing obligations associated with the APA. As of September 30, 2026, the Company is unable to estimate the timing or likelihood of achieving the regulatory milestone payments, sales-based milestone payments, and the quarterly royalty payments.
v3.26.3
Net Loss per Share
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net loss $(208,385)$(231,793)$(613,509)$(860,414)
Basic and diluted weighted average number of shares of common stock outstanding798,197,278 743,415,917 784,027,255 741,388,536 
Basic net loss per share $(0.26)$(0.31)$(0.78)$(1.16)
Diluted net loss per share $(0.26)$(0.31)$(0.78)$(1.16)

Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the diluted net loss by the weighted-average number of common shares outstanding for the period, including potentially dilutive common shares. Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods, as the inclusion of all potential common share equivalents outstanding would have been anti-dilutive.

The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive:

September 30,
20262025
Options to purchase common stock116,448,660114,097,495
Restricted stock units
730,000— 
Shares expected to be purchased under employee stock purchase plan162,86365,905
Total117,341,523114,163,400

Stock options that are outstanding and contain improbable vesting criteria are excluded from the presentation of common stock equivalents outstanding in the table above.
v3.26.3
Fair Value Measurements and Short-Term Investments
9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Fair Value Measurements and Short-Term Investments Fair Value Measurements and Short-Term Investments
The following tables set forth the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025:

September 30, 2026
Fair Value Hierarchy Level
Amortized CostUnrealized GainUnrealized (Loss)Credit (Loss)Fair Value
Financial assets included within cash and cash equivalents:
Money market fundsLevel 1$143,256 $— $— $— $143,256 
Financial assets included within short-term investments:
Certificate of deposit
Level 2150,713 — — — 150,713 
U.S. Government treasury billsLevel 2328,375 — (112)— 328,263 
Total$622,344 $— $(112)$— $622,232 

December 31, 2025
Fair Value Hierarchy Level
Amortized CostUnrealized GainUnrealized (Loss)Credit (Loss)Fair Value
Financial assets included within cash and cash equivalents:
Money market fundsLevel 1$163,588 $— $— $— $163,588 
U.S. Government treasury bills
Level 2
45,300 12 — — 45,312 
Financial assets included within short-term investments:
Certificate of deposit
Level 225,000 — — — 25,000 
U.S. Government treasury billsLevel 2463,022 160 — — 463,182 
Total$696,910 $172 $— $— $697,082 

The tables above do not include cash at September 30, 2026 and December 31, 2025 of $7,555 and $16,366, respectively.

The Company believes that the carrying amounts of prepaid expenses and other current assets, accounts payable, and accrued liabilities approximate their fair values due to the short-term nature of those instruments.

Realized gain (loss) on short-term investments for the three and nine months ended September 30, 2026 and 2025 were de minimis, respectively.
v3.26.3
Research and Development Prepaid Expenses and Accrued Liabilities
9 Months Ended
Sep. 30, 2026
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Research and Development Prepaid Expenses and Accrued Liabilities Research and Development Prepaid Expenses and Accrued Liabilities
Included within prepaid expenses and other current assets at September 30, 2026 and December 31, 2025 is $26,223 and $3,996, respectively, of prepayments relating to research and development expenditures. Included within accrued liabilities at September 30, 2026 and December 31, 2025 is $53,210 and $31,498, respectively, relating to research and development expenditures.

These amounts are determined based on the estimated costs to complete each study or activity related to the ongoing clinical trials for ivonescimab, the estimation of the current stage of completion and the invoices received, as well as predetermined
milestones which are not reflective of the current stage of development for prepaid expenses. However, accrued liabilities increase as the activities progress. The key sensitivity is the estimated current stage of completion of each study or activity, which is based on information received from the supplier and the Company’s operational knowledge of the work completed under those contracts.
v3.26.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Preferred Stock

As of September 30, 2026 and December 31, 2025, the Company had 20,000,000 shares of preferred stock, par value $0.01, authorized and no shares issued and outstanding.

Common Stock

As of September 30, 2026 and December 31, 2025, the Company had authorized 1,000,000,000 shares of common stock.

October 2025 Private Investment in Public Equity (PIPE)

On October 21, 2025, the Company entered into securities purchase agreements (the “October 2025 Purchase Agreements”) with multiple biotech institutional investors and individual accredited investors, for the sale by the Company in a private placement for an aggregate of 26,682,846 shares of the Company’s common stock, par value $0.01 per share of common stock, at purchase price of $18.74 per share, which was the closing price of the common stock on October 21, 2025, for aggregate gross proceeds to the Company of approximately $500,037, with immaterial offering costs. The private placement transaction was completed in October 2025.

All of the Company's Section 16 officers participated in the capital raise. The Company’s Co-CEO, Executive Chairman and majority stockholder, its Co-CEO and the President and member of the Board, its COO, CFO, and member of the Board, its CAO, and certain non-executive employees and other related persons purchased an aggregate of 14,514,402 shares of common stock for gross proceeds of approximately $272,000. Additionally, Akeso purchased 533,617 shares of common stock for gross proceeds of approximately $10,000. The remaining $218,037 was raised with multiple leading biotech institutional investors.

The October 2025 Purchase Agreements contain customary representations, warranties and covenants by the Company, customary indemnification obligations of the Company, including for liabilities under the Securities Act, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the October 2025 Purchase Agreements were made only for purposes of the October 2025 Purchase Agreements and as of specific dates, were solely for the benefit of the parties to such agreements and were subject to limitations agreed upon by the contracting parties.

On October 21, 2025, in connection with the October 2025 Purchase Agreements, the Company entered into Registration Rights Agreements with the Investors (the “October 2025 Registration Rights Agreements”). The October 2025 Registration Rights Agreements provide, among other things, that the Company will as soon as reasonably practicable, and in any event by no later than December 19, 2025, file with the SEC a registration statement registering the resale of the shares. The Company filed the registration statement on October 29, 2025, which was automatically effective upon filing.

At-the-Market Offering (ATM Offering)

On May 13, 2024, the Company entered into an at-the-market (“ATM”) sales agreement (the “Original Distribution Agreement”) pursuant to which the Company may, subject to the terms and conditions set forth in the agreement offer and sell, from time to time, through or to the agents, acting as agents or principal, shares of the Company’s common stock, par value $0.01, having an aggregate offering price of up to $90,000. On August 11, 2025, the Company entered into an amendment (the “Amendment”) to the Original Distribution Agreement (as amended, the “Distribution Agreement”), which among other things, increased the aggregate offering price of common stock that the Company may offer and sell from time
to time through the sales agent under the Distribution Agreement by an additional $360,000. As of September 30, 2026, the company fully utilized the proceeds available under the Distribution Agreement.

On July 23, 2026, the Company entered into an ATM sales agreement (the “Second Distribution Agreement”), pursuant to which the Company may offer and sell, from time to time, through the sales agent, shares of the Company's common stock, par value $0.01 per share, having an aggregate offering price of up to $380,000.

From the date of the Original Distribution Agreement through September 30, 2026, the Company sold 29,778,022 shares of common stock under the ATM at a weighted-average price of $15.98 per share, for gross proceeds of $475,708, with commissions and fees of approximately $7,906. The remaining gross proceeds available under the Second Distribution Agreement as of September 30, 2026 were approximately $354,292. The Company plans to use the net proceeds from this offering for working capital and general corporate purposes.


Warrants

As of September 30, 2026 and December 31, 2025, the Company had no outstanding warrants. During the nine months ended September 30, 2025, warrants of 4,629,988 with a weighted average exercise price of $1.58 were exercised. During the three months ended September 30, 2025, no warrants were exercised.
v3.26.3
AstraZeneca Equity Investment
9 Months Ended
Sep. 30, 2026
Equity Method Investments and Joint Ventures [Abstract]  
AstraZeneca Equity Investment AstraZeneca Equity Investment
On September 28, 2026, the Company entered into a securities purchase agreement with AstraZeneca (the “AstraZeneca SPA”) for the issuance and sale by the Company of approximately 108,955 shares of the Company’s newly designated Class A Convertible Preferred Stock, par value $0.01 (the “Class A Preferred Stock”), at a price of $18,356.14 per share (the “AstraZeneca Equity Investment”). Each share of Class A Preferred Stock, upon issuance, is convertible into 1,000 shares of common stock, for a total of 108,955,369 shares of common stock at a conversion price of $18.3561 per share.

The conversion of the Class A Preferred Stock is subject to the expiration and termination of the applicable waiting period of the Hart‑Scott‑Rodino Antitrust Improvements Act of 1976 (“HSR”) and the Company obtaining shareholder approval to amend its certificate of incorporation to increase the number of authorized shares of common stock by 1,000,000,000 (the “Charter Amendment Proposal”). The stockholders of the Company approved the Charter Amendment Proposal on November 4, 2026. The Class A Preferred Stock and the common stock issuable on conversion are subject to a one-year lock-up period after closing.

On October 5, 2026, the Company completed the closing of the AstraZeneca Equity Investment. In connection with the closing, the Company issued the Class A Preferred Stock to AstraZeneca and received gross proceeds of $2,000,000 before issuance costs. In connection with the closing of the AstraZeneca Equity Investment, the Company entered into a registration rights agreement with AstraZeneca (the “AstraZeneca Registration Rights Agreement”). The AstraZeneca Registration Rights Agreement provides, among other things, that the Company will as soon as reasonably practicable, and in any event by no later than 60 days after closing of the AstraZeneca SPA, file with the Securities and Exchange Commission a registration statement registering the resale of the shares of common stock issuable upon the conversion of the Class A Preferred Stock.
v3.26.3
Stock-Based Compensation
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2020 Stock Award Plan

The Company currently grants stock options and restricted stock units to employees and directors under the 2020 Stock Incentive Plan (the “2020 Plan”) and formerly, the Company granted stock options under the 2016 Long Term Incentive Plan. The 2020 Plan is administered by the Compensation Committee of the Company’s Board of Directors. The 2020 Plan is intended to attract and retain employees and directors and provide an incentive for these individuals to assist the Company to achieve long-range performance goals and to enable these individuals to participate in the long-term growth of the Company.
Based on the provisions of the 2020 Plan, the number of shares of common stock available for issuance under the 2020 Plan increased by 6,400,000 shares on January 1, 2026. On September 18, 2025, the Board approved an increase of 8,000,000 shares of common stock available for issuance under the 2020 Plan (the “Incremental Pool”), which was approved by the majority of the shares voting at the Company’s Annual Meeting of Stockholders on June 10, 2026. As of September 30, 2026, there were 12,573,799 shares available for grant under the 2020 Plan.

On May 3, 2024, the Board adopted the 2024 Inducement Pool (the “Inducement Pool”), which mirrors the terms of the 2020 Plan, with a total of 2,000,000 shares of common stock reserved for issuance under the Inducement Pool. Effective January 22, 2025, the number of shares of common stock available under the Inducement Pool increased by 2,000,000 shares. The Inducement Pool provides for the grant of non-qualified stock options and was approved by the Compensation Committee of the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September 30, 2026, there were 1,869,405 shares available for grant under the Inducement Pool.

Stock Options

The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2026.

Number of Options
Weighted average exercise price
Weighted average remaining contractual term (years)
Outstanding at December 31, 2025
119,464,728$4.147.8
Granted
6,588,97516.39 
Forfeited
(7,700,452)13.33 
Exercised
(1,554,591)5.32 
Outstanding at September 30, 2026
116,798,660 $4.21 7.1
Vested and expected to vest as of September 30, 2026
111,638,364 $4.12 7.0
Exercisable at September 30, 2026
68,345,699 $3.00 6.7

Restricted Stock Units

The following table summarizes the Company’s restricted stock unit activity for the nine months ended September 30, 2026.

Number of Restricted Stock Units
Weighted Average Grant Date Fair Value per Share
Outstanding at December 31, 2025
—$—
Granted
730,00016.59 
Outstanding at September 30, 2026
730,000$16.59 
Stock-Based Compensation Expense

The total stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss was as follows:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Research and development$23,856 $40,612 $72,400 $173,248 
General and administrative23,830 90,149 116,783 447,393 
Total stock-based compensation expense
$47,686 $130,761 $189,183 $620,641 

The following summarizes stock-based compensation expense associated with each of the Company’s stock-based compensation arrangements:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Stock options
$46,454 $130,457 $186,098 $619,873 
Restricted stock units
905 — 2,165 — 
Employee stock purchase plan
327 304 920 768 
Total stock-based compensation expense
$47,686 $130,761 $189,183 $620,641 

During the second quarter of 2025, the Compensation Committee of the Board of Directors approved a modification to the Company's outstanding unvested performance-based stock option awards for certain employees and executives that will require only the service-based vesting requirements to continue to be satisfied in order to become fully vested, subject to employee consent. The Company accounted for this change as a Type III modification (improbable-to-probable) in accordance with the requirements of Accounting Standards Codification Topic 718 (ASC 718). As a result, 44,488,976 options were valued on the modification date. The Company is recognizing the newly assessed measurement date fair value of the awards as compensation expense over the remaining vesting period. During the three and nine months ended September 30, 2026, the Company recognized expense of $20,067 and $100,516 respectively associated with the modification. As of September 30, 2026, the unrecognized compensation cost associated with the modification was $70,739 and is expected to be expensed over a weighted-average recognition period of approximately 1.0 year.
v3.26.3
Related Party Transactions
9 Months Ended
Sep. 30, 2026
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
Leases

July 25, 2022 First Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.

On July 25, 2022 the Company entered into a first amendment, dated July 19, 2022, to its existing sublease agreement with Maky Zanganeh and Associates, Inc. (“MZA”), an entity owned by Maky Zanganeh, consisting of 4,500 square feet of office space at 2882 Sand Hill Road, Menlo Park, California. The existing sublease term, which was set to expire on September 30, 2022, was extended for a period of thirty-nine months from October 1, 2022 through December 31, 2025. The rent payable under the terms of the sublease was equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up had been applied. The agreement was further amended to include additional space, as noted below under the August 2, 2024 Third Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc. The first amendment was not extended following its expiration on December 31, 2025. During the three and nine months ended September 30, 2025, payments of $207 and $621, respectively, were made pursuant to the first and third amendments to the Sublease Agreement.
July 29, 2022 Second Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.

On July 29, 2022, the Company entered into a second amendment to its existing sublease agreement with MZA, described above. The second amendment was effective as of August 1, 2022 and expired on December 31, 2025. The second amendment included an additional 1,277 square feet of office space at 2882 Sand Hill Road, Menlo Park, California. The rent payable under the terms of the sublease was equivalent to the proportionate share of the net payable by MZA to the third-party landlord, based on the square footage of office space sublet by the Company, and no mark-up had been applied. The second amendment was not extended following its expiration on December 31, 2025. During the three and nine months ended September 30, 2025, payments of $59 and $173, respectively, were made pursuant to the second amendment to the Sublease Agreement.

April 1, 2024 Miami Sublease Agreements

On April 1, 2024, the Company entered into two sublease agreements of its Miami headquarters location, one with Genius 24C Inc. (“Genius”), an affiliate of the Company’s Co-CEO, Robert W. Duggan (the “Genius Sublease Agreement”) and one with Duggan Investments Research LLC (“Investments Research”), also an affiliate of the Company's Co-CEO, Robert W. Duggan (the “Investments Research Sublease Agreement”). Pursuant to the Genius Sublease Agreement, Genius sublet from the Company 848 square feet of office space in the Miami HQ for a sixty-two month term for total rental payments of approximately $446. Pursuant to the Investments Research Sublease Agreement, Investments Research sublet from the Company 848 square feet of office space in the Miami HQ for a sixty-two month term for total rental payments of approximately $446. Effective April 1, 2026, the Company provided notice to both Genius and Investments Research to terminate the Genius Sublease Agreement and Investments Research Sublease Agreement, respectively, in order to have more space for the Company’s use at Miami HQ. The Company did not incur any early termination penalties. For the nine months ended September 30, 2026, the Company recognized sublease income of $48, which was recorded net of operating lease expenses. For the three and nine months ended September 30, 2025, the Company recognized sublease income of $46 and $140, respectively, which was recorded net of operating lease expenses. As of December 31, 2025, sublease income receivable recorded as a component of prepaid expenses and other current assets on the unaudited condensed consolidated balance sheet was de minimis.

August 2, 2024 Third Amendment to Sublease Agreement with Maky Zanganeh and Associates, Inc.

On August 2, 2024, the Company entered into a third amendment to its existing sublease agreement with MZA. The third amendment was effective August 1, 2024 and included an additional space of 145 square feet of office space located at 2882 Sand Hill Road, Menlo Park, California. The Company was obligated to pay its proportionate share of the net payable by MZA to the third-party landlord, which was revised to 93.6% as of the effective date, based on the square footage of office space sublet by the landlord. The third amendment was not extended following its expiration on December 31, 2025.

November 4, 2026 Sublease Agreement with Genius 24C, Inc.
On November 4, 2026, the Company entered into a sublease agreement with Genius, an affiliate of the Company’s Co-CEO, Robert W. Duggan (the “2026 Genius Sublease Agreement”). Pursuant to the 2026 Genius Sublease Agreement, effective November 1, 2026, the Company sublet from Genius 2,382 square feet of office space in the same facility as the Company’s headquarters in Miami, Florida for a twelve month term for a total rental payment of approximately $205.

Akeso Agreements

Upon the closing of the License Agreement, the Board appointed Dr. Yu (Michelle) Xia to serve as a member of the Board pursuant to the terms of the License Agreement. Dr. Xia is the founder of Akeso, and has been the chairwoman, president and CEO of Akeso since its inception in 2012. Furthermore, in connection with the License Agreement, the Company agreed to purchase a certain portion of drug substance for clinical and commercial supply and to enter into a supply agreement with Akeso. Refer to Note 4 for details on the License Agreement. In addition to the License Agreement , the Company also entered into various clinical services agreements with Akeso. During the three and nine months ended September 30, 2026,
the Company incurred research and development expenses of $23,395 and $65,985, respectively, under these agreements with Akeso. During the three and nine months ended September 30, 2025, the Company incurred research and development expenses of $13,657 and $29,272, respectively, under these agreements with Akeso. As of September 30, 2026 and December 31, 2025, the Company included in accrued liabilities, related to Akeso, $2,772 and $1,215, respectively.

Financings

October 2025 PIPE

Refer to Note 9 for a discussion on the participation by related parties in October 2025 PIPE.

ATM Offering

During the second quarter of 2026, the Audit Committee and all independent directors of the Board of Directors approved one or more Company affiliates to purchase shares of the Company’s common stock under the ATM. During the nine months ended September 30, 2026, the Company’s Co-Chief Executive Officers and Chief Financial Officer and Chief Operating Officer purchased an aggregate of 3,960,000 shares of common stock under the ATM at a weighted-average price of $13.17 per share, for gross proceeds totaling $52,169.

Warrants Exercise

In March 2025, Mr. Duggan, the Company’s Co-Chief Executive Officer, exercised 2,936,221 of the 3,985,055 warrants which he received in connection with a private placement completed by the Company with Mr. Duggan and other investors on December 24, 2019, resulting in the purchase of 2,936,221 shares of common stock at an exercise price of $1.58.

On April 8, 2025, Mr. Duggan completed the exercise of the remaining warrants received in the December 24, 2019 private placement, resulting in the purchase of 1,048,834 shares of common stock at an exercise price of $1.58.

Professional Services

During the nine months ended September 30, 2026 and 2025, the Company engaged the law firm Wilson Sonsini Goodrich & Rosati P.C. (“WSGR”), where Mr. Kenneth A. Clark, a member of the Board, is a partner. Payments to be made by the Company to WSGR were approved by the Audit Committee in accordance with its Related Party Transaction Policy. For the three and nine months ended September 30, 2026, the Company incurred costs related to legal services rendered by WSGR totaling approximately $174 and $209, respectively. For the three and nine months ended September 30, 2025, the Company incurred expenses for legal services rendered by WSGR totaling approximately $723 and $1,354, respectively.
v3.26.3
Commitments and Contingencies
9 Months Ended
Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Fixed Asset Purchase Commitments

There were no material changes to the Company’s capital commitments that were disclosed in the Company’s Annual Report.

Lease Commitments

On July 23, 2025, the Company entered into an operating lease for 8,857 square feet of office space in Princeton, New Jersey (the “Princeton Lease Agreement”). The term of the Princeton Lease Agreement commenced on August 18, 2025 and was set to expire on August 31, 2028. The average annual lease payments under the Princeton Lease Agreement are approximately $292. Subsequently, on April 15, 2026, the Company entered into an amendment to the Princeton Lease Agreement (the “Princeton Amendment”). The Princeton Amendment expands the office space by 6,350 square feet for a total 15,207 square feet, and extends the lease term through August 31, 2029. The average annual lease payments under the Princeton Lease Agreement, upon effect of the Princeton Amendment, will be approximately $507.
Except as noted above, there were no material changes to the Company’s lease commitments that were disclosed in the Company’s Annual Report.

Other Commitments
The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. Most contracts provide for termination upon notice, and therefore are cancellable contracts. The majority of these commitments are due within one year. There have been no material changes to the Company’s other contractual commitments that were disclosed in the Company’s Annual Report.

The Company has certain commitments under its agreements with Akeso. The License Agreement also contains certain manufacturing and purchase commitments. As of September 30, 2026, the Company is unable to estimate the amount, timing or likelihood of achieving the milestones, making future product sales or assessing estimated forecasts for manufacturing and supplied materials which these contingent payment obligations relate to.
v3.26.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.3
Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)
9 Months Ended
Sep. 30, 2026
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Accordingly, certain information and disclosures required by U.S. GAAP for complete consolidated financial statements are not included herein. All intercompany accounts and transactions have been eliminated in consolidation. The interim financial data as of September 30, 2026 and for the three and nine months ended September 30, 2026 are unaudited; however, in the opinion of management, the interim data includes all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The condensed consolidated balance sheet presented as of December 31, 2025 has been derived from the consolidated audited financial statements as of that date. The results of the period are not necessarily indicative of full year results or any other interim period. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto of the Company which are included in the Company’s Annual Report. The financial results of the Company’s activities are reported in United States Dollars.
Use of Estimates
Use of Estimates

The preparation of these unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued research and development expenses, stock-based compensation, and income taxes. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”) which requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures. The guidance is to be applied prospectively, with the option for retrospective application and is effective for public business entities for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s consolidated financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, “Narrow-Scope Improvements”, which is intended to improve the navigability of the guidance in ASC 270 and clarify when the guidance is applicable. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this standard on the Company’s consolidated financial statements and related disclosures.

Other recent authoritative guidance issued by the FASB (including technical corrections to the FASB ASC), the American Institute of Certified Public Accountants, and the SEC did not or are not expected to have a material impact on the Company’s consolidated financial statements and related disclosures.
v3.26.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Significant Expenses of the CODM Function The CODM function is regularly provided with the following significant segment expenses:
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Oncology clinical trial related costs$122,612 $75,236 $327,146 $179,423 
Compensation related costs, excluding stock-based compensation32,688 21,469 87,116 54,123 
Stock-based compensation47,686 130,761 189,183 620,641 
Other expenses (1)
11,625 6,745 26,874 15,312 
Total segment expenses214,611 234,211 630,319 869,499 
Other income, net6,226 2,418 16,810 9,085 
Net loss$(208,385)$(231,793)$(613,509)$(860,414)

(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.
v3.26.3
Other Income, Net (Tables)
9 Months Ended
Sep. 30, 2026
Other Income and Expenses [Abstract]  
Schedule of Other Income, Net
The following table sets forth the components of other income, net:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Foreign currency loss $(273)$(362)$(425)$(484)
Investment income (1)
6,499 2,780 16,735 9,622 
Other (2)
— — 500 (53)
Total
$6,226 $2,418 $16,810 $9,085 

(1) Investment income relates to the Company’s money market funds, certificate of deposit and U.S. government treasury bills. Refer to Note 7 for details.

(2) In June 2026, the Company entered into an asset purchase agreement (the “APA”) with a third party. Pursuant to the APA, the Company sold the asset relating to the pharmaceutical compound known as ridinilazole. In consideration for such assignment of rights, the third party has made an upfront non-refundable payment to the Company of $500. Additionally, the third party has also agreed to make additional payments totaling $1,500 that are contingent upon the achievement of certain regulatory milestones, sales-based milestone payments of up to $103,000, as well as quarterly royalty payments that are based on a single digit percentage of net sales for certain products covered by the assigned and transferred patent rights. The Company did not have any amounts capitalized related to the underlying portfolio of patents, nor was any write-down of assets recorded upon executing the APA. The Company received the payment of $500 from the third party in June 2026 and recognized the $500 within other income, net on the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2026. The Company does not have any ongoing obligations associated with the APA. As of September 30, 2026, the Company is unable to estimate the timing or likelihood of achieving the regulatory milestone payments, sales-based milestone payments, and the quarterly royalty payments.
v3.26.3
Net Loss per Share (Tables)
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Computation of Net Loss Per Share
The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Net loss $(208,385)$(231,793)$(613,509)$(860,414)
Basic and diluted weighted average number of shares of common stock outstanding798,197,278 743,415,917 784,027,255 741,388,536 
Basic net loss per share $(0.26)$(0.31)$(0.78)$(1.16)
Diluted net loss per share $(0.26)$(0.31)$(0.78)$(1.16)
Schedule of Potentially Dilutive Securities Excluded From the Computation of Loss Per Share
The following potentially dilutive securities were excluded from the computation of the diluted net loss per share of common stock for the periods presented because their effect would have been anti-dilutive:

September 30,
20262025
Options to purchase common stock116,448,660114,097,495
Restricted stock units
730,000— 
Shares expected to be purchased under employee stock purchase plan162,86365,905
Total117,341,523114,163,400
v3.26.3
Fair Value Measurements and Short-Term Investments (Tables)
9 Months Ended
Sep. 30, 2026
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis
The following tables set forth the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025:

September 30, 2026
Fair Value Hierarchy Level
Amortized CostUnrealized GainUnrealized (Loss)Credit (Loss)Fair Value
Financial assets included within cash and cash equivalents:
Money market fundsLevel 1$143,256 $— $— $— $143,256 
Financial assets included within short-term investments:
Certificate of deposit
Level 2150,713 — — — 150,713 
U.S. Government treasury billsLevel 2328,375 — (112)— 328,263 
Total$622,344 $— $(112)$— $622,232 

December 31, 2025
Fair Value Hierarchy Level
Amortized CostUnrealized GainUnrealized (Loss)Credit (Loss)Fair Value
Financial assets included within cash and cash equivalents:
Money market fundsLevel 1$163,588 $— $— $— $163,588 
U.S. Government treasury bills
Level 2
45,300 12 — — 45,312 
Financial assets included within short-term investments:
Certificate of deposit
Level 225,000 — — — 25,000 
U.S. Government treasury billsLevel 2463,022 160 — — 463,182 
Total$696,910 $172 $— $— $697,082 
v3.26.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
The following table summarizes the Company’s stock option activity for the nine months ended September 30, 2026.

Number of Options
Weighted average exercise price
Weighted average remaining contractual term (years)
Outstanding at December 31, 2025
119,464,728$4.147.8
Granted
6,588,97516.39 
Forfeited
(7,700,452)13.33 
Exercised
(1,554,591)5.32 
Outstanding at September 30, 2026
116,798,660 $4.21 7.1
Vested and expected to vest as of September 30, 2026
111,638,364 $4.12 7.0
Exercisable at September 30, 2026
68,345,699 $3.00 6.7
Schedule of Restricted Stock Units Activity
The following table summarizes the Company’s restricted stock unit activity for the nine months ended September 30, 2026.

Number of Restricted Stock Units
Weighted Average Grant Date Fair Value per Share
Outstanding at December 31, 2025
—$—
Granted
730,00016.59 
Outstanding at September 30, 2026
730,000$16.59 
Schedule of Stock-Based Compensation Expense
The total stock-based compensation expense included in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss was as follows:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Research and development$23,856 $40,612 $72,400 $173,248 
General and administrative23,830 90,149 116,783 447,393 
Total stock-based compensation expense
$47,686 $130,761 $189,183 $620,641 

The following summarizes stock-based compensation expense associated with each of the Company’s stock-based compensation arrangements:

Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
Stock options
$46,454 $130,457 $186,098 $619,873 
Restricted stock units
905 — 2,165 — 
Employee stock purchase plan
327 304 920 768 
Total stock-based compensation expense
$47,686 $130,761 $189,183 $620,641 
v3.26.3
Organization (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 05, 2026
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Net loss   $ 208,385 $ 215,700 $ 189,424 $ 231,793 $ 565,708 $ 62,913 $ 613,509 $ 860,414  
Net cash used in operating activities               423,229 220,992  
Accumulated deficit   2,907,668           2,907,668   $ 2,294,159
Cash and cash equivalents   150,811     $ 238,554     150,811 $ 238,554 225,266
Short-term investments   $ 478,976           $ 478,976   $ 488,182
Preferred Class A | Subsequent event | AstraZeneca Stock Purchase Agreement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Preferred stock gross proceeds $ 2,000,000                  
v3.26.3
Segment Reporting - Narrative (Details)
9 Months Ended
Sep. 30, 2026
segment
Segment Reporting [Abstract]  
Number of operating segments 1
Number of reportable segments 1
v3.26.3
Segment Reporting - Schedule of Significant Expenses of the CODM Function (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]                
Oncology clinical trial related costs [1] $ 169,131     $ 131,096     $ 459,482 $ 390,382
Stock-based compensation 47,686     130,761     189,183 620,641
Total operating expenses 214,611     234,211     630,319 869,499
Other income, net 6,226     2,418     16,810 9,085
Net loss (208,385) $ (215,700) $ (189,424) (231,793) $ (565,708) $ (62,913) (613,509) (860,414)
Reportable Segment                
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]                
Oncology clinical trial related costs 122,612     75,236     327,146 179,423
Compensation related costs, excluding stock-based compensation 32,688     21,469     87,116 54,123
Stock-based compensation 47,686     130,761     189,183 620,641
Other expenses 11,625     6,745     26,874 15,312
Total operating expenses 214,611     234,211     630,319 869,499
Other income, net 6,226     2,418     16,810 9,085
Net loss $ (208,385)     $ (231,793)     $ (613,509) $ (860,414)
[1] Refer to Note 12 – Related Party Transactions for expenses incurred.
v3.26.3
Akeso License and Collaboration Agreement (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 06, 2023
Jan. 31, 2023
Sep. 30, 2024
Sep. 30, 2026
Dec. 31, 2025
Jun. 03, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Common stock par value (in dollars per share)   $ 0.01   $ 0.01 $ 0.01  
Collaborative arrangement, transaction with party to collaborative arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Collaborative arrangement, upfront payment   $ 500,000        
Payments to Akeso for upfront milestone payments     $ 15,000      
Additional potential commercial milestone payments           $ 55,000
Collaborative arrangement, maximum milestone payments           4,555,000
Collaborative arrangement, potential regulatory milestone payments           1,050,000
Collaborative arrangement, potential commercial milestone payments           $ 3,505,000
Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Cash payment for collaborative arrangement, upfront payment   $ 274,900        
Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares)   10,000,000        
Collaborative arrangement, upfront payment, value paid in shares   $ 25,100        
Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment two            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Cash payment for collaborative arrangement, upfront payment $ 200,000          
v3.26.3
Other Income, Net (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Other Income and Expenses [Abstract]          
Foreign currency loss   $ (273) $ (362) $ (425) $ (484)
Investment income   6,499 2,780 16,735 9,622
Other   0 0 500 (53)
Total   $ 6,226 $ 2,418 16,810 $ 9,085
Payment for sale of patent $ 500        
Gain on patent sale       $ 500  
Third Party          
Other Income, Net [Line Items]          
Sale of intangible asset, contingent consideration receivable, regulatory milestones 1,500        
Sale of intangible asset, contingent consideration receivable, sales milestones $ 103,000        
v3.26.3
Net Loss per Share - Schedule of Computation of Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Earnings Per Share [Abstract]                
Net loss $ (208,385) $ (215,700) $ (189,424) $ (231,793) $ (565,708) $ (62,913) $ (613,509) $ (860,414)
Basic weighted average number of shares of common stock outstanding (in shares) 798,197,278     743,415,917     784,027,255 741,388,536
Diluted weighted average number of shares of common stock outstanding (in shares) 798,197,278     743,415,917     784,027,255 741,388,536
Basic net loss per share (in dollars per share) $ (0.26)     $ (0.31)     $ (0.78) $ (1.16)
Diluted net loss per share (in dollars per share) $ (0.26)     $ (0.31)     $ (0.78) $ (1.16)
v3.26.3
Net Loss per Share - Schedule of Potentially Dilutive Securities Excluded From the Computation of Loss Per Share (Details) - shares
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted loss per share (in shares) 117,341,523 114,163,400
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted loss per share (in shares) 116,448,660 114,097,495
Restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted loss per share (in shares) 730,000 0
Shares expected to be purchased under employee stock purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted loss per share (in shares) 162,863 65,905
v3.26.3
Fair Value Measurements and Short-Term Investments - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost $ 622,344 $ 696,910
Unrealized Gain 0 172
Unrealized (Loss) (112) 0
Credit (Loss) 0 0
Fair Value 622,232 697,082
Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 143,256 163,588
Unrealized Gain 0 0
Unrealized (Loss) 0 0
Credit (Loss) 0 0
Fair Value 143,256 163,588
Level 2 | Certificate of deposit    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 150,713 25,000
Unrealized Gain 0 0
Unrealized (Loss) 0 0
Credit (Loss) 0 0
Fair Value 150,713 25,000
Level 2 | U.S. Government treasury bills    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost 328,375 463,022
Unrealized Gain 0 160
Unrealized (Loss) (112) 0
Credit (Loss) 0 0
Fair Value $ 328,263 463,182
Level 2 | U.S. Government treasury bills    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Amortized Cost   45,300
Unrealized Gain   12
Unrealized (Loss)   0
Credit (Loss)   0
Fair Value   $ 45,312
v3.26.3
Fair Value Measurements and Short-Term Investments - Narrative (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Fair Value Disclosures [Abstract]    
Cash $ 7,555 $ 16,366
v3.26.3
Research and Development Prepaid Expenses and Accrued Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2026
Dec. 31, 2025
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Prepaid research and development expenditures $ 26,223 $ 3,996
Accrued research and development expenditure $ 53,210 $ 31,498
v3.26.3
Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 29 Months Ended
Jul. 23, 2026
Oct. 21, 2025
Aug. 11, 2025
May 13, 2024
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Dec. 31, 2025
Jan. 31, 2023
Capital Unit [Line Items]                    
Preferred stock, shares authorized (in shares)           20,000,000   20,000,000 20,000,000  
Preferred stock, par value (in dollars per share)           $ 0.01   $ 0.01 $ 0.01  
Preferred stock, shares issued (in shares)           0   0 0  
Preferred stock, shares outstanding (in shares)           0   0 0  
Common stock, shares authorized (in shares)           1,000,000,000   1,000,000,000 1,000,000,000  
Common stock par value (in dollars per share)           $ 0.01   $ 0.01 $ 0.01 $ 0.01
Proceeds from the issuance of common stock [1]           $ 320,241 $ 31,764      
Warrants outstanding and exercisable (in shares)           0   0 0  
Warrants exercised (in shares)         0   4,629,988      
Weighted average exercise price of warrants exercised (in dollars per share)             $ 1.58      
Affiliated entity                    
Capital Unit [Line Items]                    
Shares issued in transaction (in shares)   14,514,402                
Proceeds from the issuance of common stock   $ 272,000                
Related Party                    
Capital Unit [Line Items]                    
Shares issued in transaction (in shares)   533,617                
Proceeds from the issuance of common stock   $ 10,000                
Nonrelated Party                    
Capital Unit [Line Items]                    
Sale of stock aggregate price   $ 218,037                
Private placement                    
Capital Unit [Line Items]                    
Shares issued in transaction (in shares)   26,682,846                
Common stock par value (in dollars per share)   $ 0.01                
Sale of stock price (in dollars per share)   $ 18.74                
Proceeds from the issuance of common stock   $ 500,037                
Original Distribution Agreement                    
Capital Unit [Line Items]                    
Common stock par value (in dollars per share)       $ 0.01            
Sale of stock, aggregate offering price       $ 90,000            
Distribution Agreement                    
Capital Unit [Line Items]                    
Shares issued in transaction (in shares)               29,778,022    
Sale of stock price (in dollars per share)           $ 15.98   $ 15.98    
Proceeds from the issuance of common stock               $ 475,708    
Sale of stock, aggregate offering price     $ 360,000              
Issuance costs               7,906    
Remaining availability under the offering           $ 354,292   $ 354,292    
Second Distribution Agreement                    
Capital Unit [Line Items]                    
Common stock par value (in dollars per share) $ 0.01                  
Sale of stock, aggregate offering price $ 380,000                  
[1] Refer to Note 12 – Related Party Transactions
v3.26.3
AstraZeneca Equity Investment (Details) - USD ($)
$ / shares in Units, $ in Thousands
Oct. 05, 2026
Sep. 28, 2026
Sep. 26, 2026
Sep. 30, 2026
Dec. 31, 2025
Schedule of Equity Method Investments [Line Items]          
Preferred stock, par value (in dollars per share)       $ 0.01 $ 0.01
Common stock, additional shares authorized (in shares)     1,000,000,000    
Preferred Class A          
Schedule of Equity Method Investments [Line Items]          
Preferred stock, par value (in dollars per share)   $ 0.01      
Preferred Class A | AstraZeneca Stock Purchase Agreement          
Schedule of Equity Method Investments [Line Items]          
Shares issued in transaction (in shares)   108,955      
Offering price (in dollars per share)   $ 18,356.14      
Convertible preferred stock, shares issuable for each share upon conversion (in shares)   1,000      
Convertible preferred stock, shares issuable (in shares)   108,955,369      
Convertible preferred stock, conversion price (in dollars per share)   $ 18.3561      
Preferred Class A | AstraZeneca Stock Purchase Agreement | Subsequent event          
Schedule of Equity Method Investments [Line Items]          
Preferred stock gross proceeds $ 2,000,000        
v3.26.3
Stock-Based Compensation - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2025
Sep. 30, 2026
Jan. 01, 2026
Sep. 18, 2025
Jan. 22, 2025
May 03, 2024
Performance-based stock options              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares accelerated for vesting (in shares)   44,488,976          
Accelerated charges $ 20,067   $ 100,516        
Cost not yet recognized due to accelerated vesting, amount $ 70,739   $ 70,739        
Weighted average recognition period (in years)     1 year        
2020 Stock Incentive Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of additional shares allowable (in shares)       6,400,000      
Number of shares available for grant (in shares) 12,573,799   12,573,799        
Incremental Pool              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of additional shares allowable (in shares)         8,000,000    
Inducement Pool              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of additional shares allowable (in shares)           2,000,000  
Number of shares available for grant (in shares) 1,869,405   1,869,405        
Number of shares reserved for future issuance (in shares)             2,000,000
v3.26.3
Stock-Based Compensation - Schedule of Stock Option Activity (Details) - Stock options - $ / shares
9 Months Ended 12 Months Ended
Sep. 30, 2026
Dec. 31, 2025
Number of Options    
Beginning balance (in shares) 119,464,728  
Granted (in shares) 6,588,975  
Forfeited (in shares) (7,700,452)  
Exercised (in shares) (1,554,591)  
Ending balance (in shares) 116,798,660 119,464,728
Stock options vested or expected to vest (in shares) 111,638,364  
Stock options exercisable (in shares) 68,345,699  
Weighted average exercise price    
Beginning balance (in dollars per share) $ 4.14  
Granted (in dollars per share) 16.39  
Forfeited (in dollars per share) 13.33  
Exercised (in dollars per share) 5.32  
Ending balance (in dollars per share) 4.21 $ 4.14
Stock options vested or expected to vest (in dollars per share) 4.12  
Stock options exercisable (in dollars per share) $ 3.00  
Weighted average remaining contractual term (years)    
Outstanding at end of period, weighted average remaining contractual life 7 years 1 month 6 days 7 years 9 months 18 days
Vested and expected to vest at end of period, weighted average remaining contractual life 7 years  
Exercisable at end of period, weighted average remaining contractual life 6 years 8 months 12 days  
v3.26.3
Stock-Based Compensation - Schedule of Restricted Stock Units Activity (Details) - Restricted stock units
9 Months Ended
Sep. 30, 2026
$ / shares
shares
Number of Restricted Stock Units  
Beginning balance (in shares) | shares 0
Granted (in shares) | shares 730,000
Ending balance (in shares) | shares 730,000
Weighted Average Grant Date Fair Value per Share  
Beginning balance (in dollars per share) | $ / shares $ 0
Granted (in dollars per share) | $ / shares 16.59
Ending balance (in dollars per share) | $ / shares $ 16.59
v3.26.3
Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense $ 47,686 $ 130,761 $ 189,183 $ 620,641
Stock options        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 46,454 130,457 186,098 619,873
Restricted stock units        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 905 0 2,165 0
Employee stock purchase plan        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 327 304 920 768
Income Statement Location [Axis]: us-gaap:GeneralAndAdministrativeExpense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense 23,830 90,149 116,783 447,393
Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Total stock-based compensation expense $ 23,856 $ 40,612 $ 72,400 $ 173,248
v3.26.3
Related Party Transactions (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Nov. 01, 2026
USD ($)
ft²
Oct. 21, 2025
$ / shares
shares
Apr. 08, 2025
$ / shares
shares
Aug. 01, 2024
ft²
Apr. 01, 2024
USD ($)
ft²
contract
Mar. 31, 2025
$ / shares
shares
Sep. 30, 2026
USD ($)
$ / shares
Sep. 30, 2025
USD ($)
shares
Sep. 30, 2026
USD ($)
$ / shares
shares
Sep. 30, 2025
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
Jul. 29, 2022
ft²
Jul. 25, 2022
ft²
Related Party Transaction [Line Items]                          
Research and development [1]             $ 169,131 $ 131,096 $ 459,482 $ 390,382      
Accrued liabilities             $ 55,934   $ 55,934   $ 32,100    
Warrants exercised (in shares) | shares               0   4,629,988      
Weighted average exercise price of warrants exercised (in dollars per share) | $ / shares                   $ 1.58      
Private Placement                          
Related Party Transaction [Line Items]                          
Shares issued in transaction (in shares) | shares   26,682,846                      
Offering price (in dollars per share) | $ / shares   $ 18.74                      
Affiliated Entity                          
Related Party Transaction [Line Items]                          
Number of sublease contracts to other party | contract         2                
Shares issued in transaction (in shares) | shares   14,514,402                      
Related Party                          
Related Party Transaction [Line Items]                          
Shares issued in transaction (in shares) | shares   533,617                      
Executives                          
Related Party Transaction [Line Items]                          
Shares issued in transaction (in shares) | shares                 3,960,000        
Offering price (in dollars per share) | $ / shares             $ 13.17   $ 13.17        
Sale of stock aggregate price                 $ 52,169        
Co-Chief Executive Officer                          
Related Party Transaction [Line Items]                          
Warrants exercised (in shares) | shares     1,048,834     2,936,221              
Weighted average exercise price of warrants (in dollars per share) | $ / shares           $ 1.58              
Weighted average exercise price of warrants exercised (in dollars per share) | $ / shares     $ 1.58                    
Co-Chief Executive Officer | Private Placement                          
Related Party Transaction [Line Items]                          
Shares issued in transaction (in shares) | shares           3,985,055              
Wilson Sonsini Goodrich & Rosati P.C. (“WSGR”) | Director                          
Related Party Transaction [Line Items]                          
Expenses for legal services             $ 174 $ 723 209 $ 1,354      
First Amendment to Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Area of premises subleased from other party (in square feet) | ft²                         4,500
Sublease extension term from other party                         39 months
First and Third Amendment to Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Payments to related party               207   621      
Second Amendment to Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Area of premises subleased from other party (in square feet) | ft²                       1,277  
Payments to related party               59   173      
Genius Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Number of sublease contracts to other party | contract         1                
Area of premises subleased to other party (in square feet) | ft²         848                
Sublease term to other party         62 months                
Total sublease rental payments to be received         $ 446                
Investments Research Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Number of sublease contracts to other party | contract         1                
Area of premises subleased to other party (in square feet) | ft²         848                
Sublease term to other party         62 months                
Total sublease rental payments to be received         $ 446                
Genius Sublease Agreement and Investments Research Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Sublease income               46 48 140      
Third Amendment to Sublease Agreement | Affiliated Entity                          
Related Party Transaction [Line Items]                          
Area of premises subleased from other party (in square feet) | ft²       145                  
Proportionate share of net payable       93.60%                  
Genius 2026 Sublease Agreement | Co-Chief Executive Officer | Subsequent event                          
Related Party Transaction [Line Items]                          
Sublease term to other party 12 months                        
Operating lease, office space (in square feet) | ft² 2,382                        
Sublease annual rental payment $ 205                        
Akeso Supply Agreement | Related Party                          
Related Party Transaction [Line Items]                          
Research and development             23,395 $ 13,657 65,985 $ 29,272      
Accrued liabilities             $ 2,772   $ 2,772   $ 1,215    
[1] Refer to Note 12 – Related Party Transactions for expenses incurred.
v3.26.3
Commitments and Contingencies (Details)
$ in Thousands
Apr. 15, 2026
USD ($)
ft²
Sep. 30, 2026
Jul. 23, 2025
USD ($)
ft²
Loss Contingencies [Line Items]      
Period for which the majority of contractual commitments are to be paid (in years)   1 year  
Princeton Office Lease      
Loss Contingencies [Line Items]      
Operating lease, office space (in square feet) 15,207   8,857
Lease, average annual lease payments | $ $ 507   $ 292
Increase in area of real estate property (in square feet) 6,350